HIV "Salvage" Drug Efficacy May Be Shown With Half-Log Drop In Viral Load
Executive Summary
A .5-log drop in viral load may be an optimal endpoint for testing "salvage" therapies in treatment-experienced HIV patients, FDA's Antiviral Drugs Advisory Committee concluded.
You may also be interested in...
HIV Trial Modified Factorial Design Best For Study In Treated Patients - Cmte.
Modified factorial trial designs are the best strategy for studying new therapies in heavily treated HIV patients, FDA's Antiviral Drugs Advisory Committee suggested.
HIV Trial Modified Factorial Design Best For Study In Treated Patients - Cmte.
Modified factorial trial designs are the best strategy for studying new therapies in heavily treated HIV patients, FDA's Antiviral Drugs Advisory Committee suggested.
Viral Load May Be Best Biomarker For IBTs, Antiviral Advisory Cmte Suggests
Viral load is probably the best available biomarker for the clinical efficacy of immune-based therapies, provided changes in plasma HIV RNA levels can be linked with a therapy's immunological benefit, FDA's Antiviral Drugs Advisory Committee suggested.